Long-term genetic tracking of patients with chronic blood cancers is revealing hidden patterns in how these diseases develop ...
A review of management strategies for patients with polycythemia vera and myelofibrosis was presented at the 2026 ONA Summit.
Tracking how blood cancers develop over time has uncovered important genetic differences between patients whose disease stays ...
Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June MADRID and CAMBRIDGE, Mass., April ...
Some blood cancers move with eerie patience. A patient can feel well for years, their blood counts looking steady, their ...
Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, boosting blood cancer pipeline with a Phase 1 JAK2 inhibitor for ...
Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms ...
Lilly is set to acquire Ajax Therapeutics for up to $2.3B, gaining a novel JAK2 inhibitor as it ramps up oncology bets and ...
Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...
Children with Down syndrome are at high risk of developing myeloid leukemia. A research team from Goethe University Frankfurt, Wellcome Sanger Institute, Great Ormond Street Hospital, and their ...
The acquisition is the latest in a series of recent deals that Indianapolis-based Eli Lilly and Co. has made to increase its cancer-treatment pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results